Cloud-Clone adds allergy research portfolio before peak rhinitis season
Cloud-Clone Corp. launched a bundled allergy research portfolio aimed at pre-clinical study of allergic rhinitis, asthma and other type-2 airway inflammatory disorders. The offering combines assays, proteins, antibodies, animal-model services and contract testing for work in human and animal samples.
Why it matters: - Allergic rhinitis and asthma are closely linked type-2 airway diseases, and better tools are needed to study the immune pathways that drive sneezing, congestion and airway inflammation. - Cloud-Clone’s portfolio is designed to support pre-clinical research that connects biomarker measurement, mechanistic testing and animal modeling in one workflow.
What happened: - Cloud-Clone Corp. introduced a new allergy research portfolio ahead of the fall and winter rhinitis season. - The offering is built for pre-clinical research on allergic rhinitis, asthma and allergic dermatitis. - The company says the portfolio is compatible with human, mouse, rat, rabbit and guinea-pig samples.
The details: - The portfolio includes six modules: ELISA kits, multiplex assays, recombinant proteins, target-specific antibodies, animal-model and in-vivo services, and contract testing services. - ELISA kits measure IgE, IL-4, IL-5, IL-13, TSLP, IL-33, IL-25, IFN-γ, IL-31, IL-17 and IL-10 in serum, plasma, tissue homogenate and bronchoalveolar-lavage fluid. - Multiplex assays on Luminex and CBA platforms are designed to quantify multiple cytokines from limited sample volumes. - Recombinant proteins include IL-4, IL-33 and TSLP for in-vitro stimulation, pathway studies and assay-standard preparation, with custom protein production available for non-stock targets. - Target-specific monoclonal and polyclonal antibodies are validated for western blot, immunohistochemistry and immunofluorescence. - The antibody offering also includes custom antibody generation and fluorophore- or enzyme-labeling services. - Animal-model and in-vivo services include SPF-facility-supported pre-clinical modeling, customizable endpoints, group design and pathological evaluation. - Contract testing services cover outsourced biochemical and cellular assays with standardized workflows and full experimental reports. - Cloud-Clone says its reagents, proteins, antibodies and animal-model services follow unified quality-control standards. - The company says assay antibodies and recombinant proteins are produced in-house to reduce batch-to-batch inconsistency. - The portfolio is built around the ovalbumin sensitization-and-challenge model, a common pre-clinical approach for allergic airway disease. - In that model, intraperitoneal OVA plus aluminium hydroxide induces allergen-specific IgE, and intranasal or aerosol OVA challenge triggers hypersensitivity reactions. - Readouts include sneezing and nasal scratching scores, nasal-tissue histopathology, eosinophilic infiltration and serum biomarkers such as IgE, IL-4 and IFN-γ. - Rats are positioned for intranasal-challenge work, while BALB/c mice are positioned for genetic and mechanistic studies. - Cloud-Clone also offers established asthma-model services and custom modelling for allergic rhinitis and allergic dermatitis. - The company pairs those services with histopathology and multi-time-point tissue collection to generate publication-grade datasets. - The portfolio is supported by a workflow that can move from model creation to serology, tissue analysis and mechanistic validation. - Cloud-Clone says its reagents and services are cited in multiple international peer-reviewed journals, with references available on the company website: the company website.
Between the lines: - The launch reflects a push toward integrated research tools that can cover both immune biomarkers and whole-animal disease behavior. - The emphasis on alarmins such as TSLP, IL-33 and IL-25 points to where current allergy-drug development is focused. - Bundling assays, antibodies, proteins and animal services can reduce the handoff friction that often slows pre-clinical allergy studies.
What's next: - Researchers can use the portfolio to screen candidate anti-allergy compounds, test mechanism of action and compare upstream alarmin effects with downstream cytokine effects. - The company is positioning the platform for ongoing work in allergic rhinitis, asthma and other airway inflammatory diseases.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Science Press Releases
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.